Di Minin et al. (2014) reported that mutp53 in cancer cells reprogram NF-κB and JNK activation in response to TNFα through the binding and interfering the tumor suppressor RasGAP Disabled 2 Interacting Protein (DAB2IP) in the cytoplasm. Mutp53 can also interact with NF-κB directly, enhancing RNA polymerase II recruitment in response to chronic TNF signaling which shapes the enhancer landscape and oncogenic gene expression (Rahnamoun et al., 2017). This evidence concerns the gene TNF and cancer.